Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT2IWF)

Drug Name

APH-1105 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Alpha-secretase (ASE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ID1201	DM3LHAX	Alzheimer disease	8A20	Phase 2	[3]
APH-1104	DMVQI2A	Alzheimer disease	8A20	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03806478) Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD). U.S.National Institutes of Health.
2	Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021 May 25;7(1):e12179.
3	Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of Melia toosendan, through activation of the phosphatidylinositol 3-kinase/Akt pathway. Environ Toxicol Pharmacol. 2014 Mar;37(2):513-20.
4	Clinical pipeline report, company report or official report of Aphios